Your Good Partner in Biology Research

  1. 首页
  2. 试剂盒
  3. 酶联免疫试剂盒
  4. Human protein-arginine deiminase type-4(PADI4) ELISA kit

Human protein-arginine deiminase type-4(PADI4) ELISA kit

  • 中文名称：
    人蛋白精氨酸脱亚氨酶4(PADI4)酶联免疫试剂盒
  • 货号：
    CSB-E16219h
  • 规格：
    96T/48T
  • 价格：
    ￥3600/￥2500
  • 其他：

产品详情

  • 产品描述：

    This Human PADI4 ELISA Kit was designed for the quantitative measurement of Human PADI4 protein in serum, urine, cell culture supernates. It is a Sandwich ELISA kit, its detection range is 0.156 ng/mL-10 ng/mL and the sensitivity is 0.039 ng/mL.

  • 别名：
    EC 3.5.3.15 ELISA Kit; HL 60 PAD ELISA Kit; HL-60 PAD ELISA Kit; PAD 4 ELISA Kit; PAD ELISA Kit; PADI 4 ELISA Kit; PADI 5 ELISA Kit; PADI H protein ELISA Kit; Padi4 ELISA Kit; PADI4_HUMAN ELISA Kit; PADI5 ELISA Kit; PDI 4 ELISA Kit; PDI 5 ELISA Kit; PDI4 ELISA Kit; PDI5 ELISA Kit; Peptidyl arginine deiminase type IV ELISA Kit; Peptidyl arginine deiminase type V ELISA Kit; Peptidylarginine deiminase IV ELISA Kit; Protein arginine deiminase ELISA Kit; Protein arginine deiminase type 4 ELISA Kit; Protein arginine deiminase type IV ELISA Kit; Protein-arginine deiminase type IV ELISA Kit; Protein-arginine deiminase type-4 ELISA Kit
  • 缩写：
    PADI4
  • Uniprot No.：
  • 种属：
    Homo sapiens (Human)
  • 样本类型：
    serum, urine, cell culture supernates
  • 检测范围：
    0.156 ng/mL-10 ng/mL
  • 灵敏度：
    0.039 ng/mL
  • 反应时间：
    1-5h
  • 样本体积：
    50-100ul
  • 检测波长：
    450 nm
  • 研究领域：
    Epigenetics and Nuclear Signaling
  • 测定原理：
    quantitative
  • 测定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 线性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human PADI4 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　SampleSerum(n=4)
    1:100Average %87
    Range %80-92
    1:200Average %99
    Range %91-105
    1:400Average %99
    Range %92-110
    1:800Average %94
    Range %86-98
  • 回收率：
    The recovery of human PADI4 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 9589-98
  • 标准曲线：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/mlOD1OD2AverageCorrected
    102.719 2.678 2.699 2.609
    52.223 2.189 2.206 2.116
    2.51.427 1.402 1.415 1.325
    1.250.782 0.763 0.773 0.683
    0.6250.407 0.379 0.393 0.303
    0.3120.249 0.239 0.244 0.154
    0.1560.158 0.148 0.153 0.063
    00.093 0.087 0.090 　
  • 本试剂盒所含材料：
    • A micro ELISA plate --- The 96-well plate has been pre-coated with an anti-human PADI4 antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
    • Two vials lyophilized standard ---Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
    • One vial Biotin-labeled PADI4 antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody.
    • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) ---Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
    • One vial Biotin-antibody Diluent (15 ml/bottle) ---Dilute the Biotin-antibody.
    • One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution.
    • One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration.
    • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) ---Wash away unbound or free substances.
    • One vial TMB Substrate (10 ml/bottle) ---Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
    • One vial Stop Solution (10 ml/bottle) ---Stop the color reaction. The solution color immediately turns from blue to yellow.
    • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
    • An instruction manual

    显示更多

    收起更多

  • 本试剂盒不含材料：
    • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
    • An incubator can provide stable incubation conditions up to 37°C±5°C.
    • Centrifuge
    • Vortex
    • Squirt bottle, manifold dispenser, or automated microplate washer
    • Absorbent paper for blotting the microtiter plate
    • 50-300ul multi-channel micropipette
    • Pipette tips
    • Single-channel micropipette with different ranges
    • 100ml and 500ml graduated cylinders
    • Deionized or distilled water
    • Timer
    • Test tubes for dilution

    显示更多

    收起更多

  • 数据处理：
  • 货期：
    3-5 working days

产品评价

靶点详情

  • 功能：
    Catalyzes the citrullination/deimination of arginine residues of proteins such as histones, thereby playing a key role in histone code and regulation of stem cell maintenance. Citrullinates histone H1 at 'Arg-54' (to form H1R54ci), histone H3 at 'Arg-2', 'Arg-8', 'Arg-17' and/or 'Arg-26' (to form H3R2ci, H3R8ci, H3R17ci, H3R26ci, respectively) and histone H4 at 'Arg-3' (to form H4R3ci). Acts as a key regulator of stem cell maintenance by mediating citrullination of histone H1: citrullination of 'Arg-54' of histone H1 (H1R54ci) results in H1 displacement from chromatin and global chromatin decondensation, thereby promoting pluripotency and stem cell maintenance. Promotes profound chromatin decondensation during the innate immune response to infection in neutrophils by mediating formation of H1R54ci. Required for the formation of neutrophil extracellular traps (NETs); NETs are mainly composed of DNA fibers and are released by neutrophils to bind pathogens during inflammation. Citrullination of histone H3 prevents their methylation by CARM1 and HRMT1L2/PRMT1 and represses transcription. Citrullinates EP300/P300 at 'Arg-2142', which favors its interaction with NCOA2/GRIP1.
  • 基因功能参考文献：
    1. Molecular interplay between the dimer interface and the substrate-binding site of human PAD4 has been reported. PMID: 28209966
    2. PADI4 may be closely associated with hypoxiainduced autophagy, and the inhibition of hypoxiainduced autophagy by PADI4 knockdown may contribute to an increase in the apoptosis of RAFLS. PMID: 29393388
    3. MiRNA-146a rs2910164 and IRAK1 rs3027898 polymorphisms were a risk factor for predisposition to Rheumatoid Arthritis in Egyptian Population in codominant and dominant tested inheritance models, while, the miRNA-499 rs3746444 and PADI4 rs1748033 polymorphisms were a risk factor in codominant and recessive one. PMID: 29734142
    4. our meta-analysis demonstrated that the PADI4_94 polymorphisms might contribute to RA susceptibility especially in Asian populations but not in Caucasian populations. PMID: 29302826
    5. Meta-analysis indicated a significantly increased association between PADI -104C/T polymorphism and rheumatoid arthritis (RA) in Chinese and Japanese populations (which were the majority of included populations in the analysis). PMID: 29518108
    6. PADI4 interacted with SYVN1 directly and that overexpression of PADI4 suppressed the ubiquitination of proteins. Thus, a reduction in ER stress induced by PADI4 may abrogate the initiation of chronic RA by suppressing the proliferative signals of RA synoviocytes. PMID: 29039504
    7. mRNA expression of PADI2, PADI4 and Sp1 is upregulated in rheumatoid arthritis bone marrow CD34+ cells independently of the systemic inflammation or treatment regimen. PMID: 29148420
    8. this study in a Southern Mexican population suggests that PADI4 individual polymorphisms and the related susceptibility haplotype (GTG) are also genetic risk markers for rheumatoid arthritis PMID: 28551357
    9. The T allele of PADI4 rs2240340 is associated with Rheumatoid Arthritis in Asians. PMID: 28653215
    10. PADI4 contributes to gastric tumorigenesis by upregulating CXCR2, KRT14 and TNF-alpha expression. PMID: 27556695
    11. In this case-control study with sufficient sample size to detect associations, we observed that PADI4 SNPS rs11203367 and rs874881 do not significantly determine RA susceptibility PMID: 27182695
    12. SNPs of PADI4 may be a risk factor for airway abnormalities in RA. PMID: 27372294
    13. this meta-analysis suggested that PADI4 -92C/G polymorphism may be associated with the rheumatoid arthritis incidence in the Chinese population, especially for South China. Further studies conducted on other ethnic groups are required for definite conclusions. PMID: 28832760
    14. PADI4 contributes to the pathogenesis of RA by protecting FLSs from apoptosis. PADI4 suppresses p21 transcription through altering histone H3 arginine modifications on p21 promoter region. PMID: 28367100
    15. Proteolysis by granzyme B enhances presentation of autoantigenic PAD4 epitopes in rheumatoid arthritis. PMID: 27700100
    16. No associations were found between clinical subtypes of JIA and PADI4 allele frequency. rs2240337 in the PADI4 gene was significantly associated with anti-cyclic citrullinated peptide antibody-positivity in juvenile idiopathic arthritis. PMID: 28182665
    17. The effect of the PADI4-104C/T polymorphism on RA risk in the Chinese population was evaluated in a meta-analysis. The overall analysis indicated a significant association between the PADI4-104C/T polymorphism and RA risk in the Chinese population (T vs C: OR = 1.45, 95%CI = 1.18-1.78; TT vs CC: OR = 1.49, 95%CI = 1.24-1.80; TT vs CC+CT: OR = 1.28, 95%CI = 1.08-1.51; TT+CT vs CC: OR = 1.75, 95%CI = 1.30-2.37). PMID: 27706751
    18. Overexpression of PAD4 constrains the activity of EMT via suppressing Elk1 expression. PMID: 27176594
    19. Our study also demonstrated that PADI4 contributes to tumor metastasis by regulating the gene expression of insulin-like growth factor 1 (IGF1) and WAS/WASL-interacting protein family member 1 (WIPF1). PMID: 26563365
    20. PAD4 levels were significantly higher in patients with rheumatoid arthritis than in patients with systemic lupus erythematosis or healthy controls. Anti-PAD4 antibodies were detected in 30% of patients with rheumatoid arthritis, but not in patients with SLE, systemic sclerosis or controls. PMID: 26415740
    21. the PADI4_94 and PADI_104 polymorphisms are associated with susceptibility to rheumatoid arthritis (RA) in Asians and Caucasians, and the PADI4_92 polymorphism is associated with susceptibility to RA in Asians, but not in Caucasians [meta-analysis] PMID: 26474773
    22. This meta-analysis showed that the PADI4 -94G/A variants may influence RA risk in the Chinese population. PMID: 27051025
    23. The results highlight an association between PAD4 and DNA hypermethylation in acute promyelocytic leukemia and demonstrate that targeting PAD4 or regulating its downstream effectors may be a promising strategy to control differentiation in the clinic. PMID: 26673819
    24. Polymorphism in exon-4 of PADI4 gene showed significant association with rheumatoid arthritis (RA)and polymorphism in exon-3 exhibited moderate association with RA. PMID: 22976394
    25. PADI4 rs1748033 gene polymorphism increased the risk of RA in a sample of the Iranian population. PMID: 26546893
    26. Silencing of PADI4 attenuates the TNF-alpha-induced osteogenic differentiation of human mesenchymal stem cells. PMID: 26082376
    27. Data show that peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides autoantibodies were detected in 24, 61 and 74% of rheumatoid arthritis (RA) patients, respectively. PMID: 26149185
    28. PAD4 activity was significantly higher in cell-free synovial fluid of rheumatoid arthritis patients compared to osteoarthritis patients. PMID: 26245941
    29. We found that heterozygote genotypes for PADI4_89 were protectively associated with susceptibility to tuberculosis. PMID: 25205591
    30. Data show that peptidyl arginine deiminase type IV (PADI4) polymorphisms and a functional haplotype are associated with rheumatoid arthritis. PMID: 25562673
    31. PAD-4 is inhibited by PTPN22. PMID: 26019128
    32. PADI4-94G/A polymorphism is associated with susceptibility to rheumatoid arthritis in the overall population and in the Asian population. PMID: 26043831
    33. We propose that the influence of PADI4 on IL6ST transcription plays a role in the control of IL6ST expression during lineage differentiation of hematopoietic stem/progenitor cells. PMID: 24874575
    34. The prevalence and extent of ILD was markedly higher among RA patients with anti-PAD3/4 cross-reactive antibodies, even after accounting for relevant confounders, particularly among ever smokers. PMID: 24901704
    35. genetic variants in CDK6 and PADI4 were associated with anti-citrullinated cyclic peptide status in rheumatoid arthritis DRB1*04 negative patients PMID: 25138370
    36. Data indicate an association between peptidylarginine deiminase PADI4 and rheumatoid arthritis (RA) in the multiethnic population from South East Asia. PMID: 23164236
    37. rADI not only reduced NO production but also caused cellular toxicity in nNOS-activated SH-SY5Y cells, suggesting a dual role for rADI in NOS-mediated neurotoxicity. PMID: 25126568
    38. PADI4 polymorphisms are risk factors contributed to rheumatoid arthritis susceptibility, especially for anti-CCP positive disease, and may confer higher risk of radiographic severity in Chinese Han population. PMID: 24564960
    39. We found that PADI4 polymorphisms are associated with RA susceptibility, regardless of ACPA titers. PMID: 24454473
    40. results suggest that the p50 subunit of NF-kappaB may play a role in the repression of PAD4 transcription during inflammation PMID: 24140127
    41. anti-PAD4 autoantibodies (identified by their cross-reactivity with PAD3) markedly increase the catalytic efficiency of PAD4. PMID: 23698378
    42. PADI4 risk allele and HLA-DRB1 shared epitope are independent genetic risks for radiographic progression in Japanese rheumatoid arthritis patients PMID: 23577190
    43. Dysregulation of PAD4-mediated citrullination of nuclear GSK3beta activates TGF-beta signaling and induces epithelial-to-mesenchymal transition in breast cancer cells. PMID: 23818587
    44. Therefore, our data strongly suggest that the N-terminal Ca(2+) ions play critical roles in the full activation of the PAD4 enzyme. PMID: 23382808
    45. Data indicate that the declined PADI4 mRNA was significantly associated with Line-1 demethylation in hepatocellular carcinoma (HCC) patients. PMID: 22907585
    46. Our results suggested that rs2240340 in PADI4 gene is associated with susceptibility to rheumatoid arthritis in Yunnan. PMID: 23450494
    47. This meta-analysis suggests that PADI4 polymorphisms represent a significant risk factor for rheumatoid arthritis, especially in Asians. PMID: 22552437
    48. The synovial expression of cyclic citrullinated peptide and the generation of anti-CCP antibodies are strongly associated with shared epitope alleles and/or certain PADI4 gene SNPs in rheumatoid arthritis. PMID: 22944128
    49. The relationship between PADI4 and rheumatoid arthritis has been observed among Japanese. PMID: 23214088
    50. No single point association between genotype and allele frequency was found for rheumatoid arthritis in Tunisia. PMID: 22459419

    显示更多

    收起更多

  • 相关疾病：
    Rheumatoid arthritis (RA)
  • 亚细胞定位：
    Cytoplasm. Nucleus. Cytoplasmic granule.
  • 蛋白家族：
    Protein arginine deiminase family
  • 组织特异性：
    Expressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes.
  • 数据库链接：

    HGNC: 18368

    OMIM: 180300

    KEGG: hsa:23569

    STRING: 9606.ENSP00000364597

    UniGene: Hs.522969